Intellia Therapeutics, Inc. (NTLA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol NTLA
- Company Intellia Therapeutics, Inc.
- Price $12.89
- Changes Percentage -4.45
- Change -0.6
- Day Low $12.54
- Day High $14.25
- Year High $28.25
- Year Low $7.31
- Market Cap $1,460,981,049
- Price Avg 50 EMA (D) $13.59
- Price Avg 200 EMA (D) $13.3
- Exchange NASDAQ
- Volume 3,018,620
- Average Volume 5,451,241
- Open $13.77
- Previous Close $13.49
- EPS -3.52
- PE -3.70
- Earnings Announcement 2026-08-06 04:00:00
- Shares Outstanding $112,210,526
Company brief: INTELLIA THERAPEUTICS, INC. (NTLA )
- Healthcare
- Biotechnology
- Dr. John M. Leonard M.D.
- https://www.intelliatx.com
- US
- N/A
- 05-06-2016
- US45826J1051
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.